DNMT3A and acute myeloid leukemia: By contrast, in a PDX model of DNMT3A-WT leukaemia (AML-372), although both LSD1i and the combo treatment led to a slight increase in survival and reduction in tumour burden, the combo treatment did not show any additional benefits over LSD1i alone (Extended Data Fig. 9e,f).